Diatom-based microrobots show promise for targeted photodynamic therapy of glioblastoma
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 13:15 ET (22-Jun-2026 17:15 GMT/UTC)
Researchers will investigate how a common dietary nutrient may control a hidden layer of gene regulation in cancer cells.
A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a more aggressive form while under active surveillance.
A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center. The findings provide important new insights into why patients with metastatic disease often stop responding to a key class of life-prolonging chemotherapy drugs after initially benefiting. Given that taxanes remain the only chemotherapy agents with demonstrated survival benefit in advanced prostate cancer, understanding how and why resistance develops is an urgent need for patients.
A new study has revealed a promising new approach to curb the spread of triple‑negative breast cancer, one of the most aggressive and difficult‑to‑treat forms of the disease.
Published recently in Cancer Letters, Gabriel Duda, Ph.D., scientific director of transplant oncology and therapeutics at Houston Methodist Research Institute, and his research team discovered pairing targeted treatments with CAR T‑cell therapy may help control cancer recurrence when intervention options are otherwise limited.